Alvotech, a Reykjavík-based BioTech firm specialising within the improvement and manufacture of biosimilar medicines, has secured a €100 million senior time period mortgage facility to strengthen liquidity and help the execution of its strategic priorities in 2026.
The time period mortgage facility bears an rate of interest of 12.50%, payable month-to-month in money, and has a maturity date of two years. The transaction, led by GoldenTree Asset Administration, replaces the corporate’s beforehand disclosed working capital facility (ABL) and offers Alvotech with entry to the complete €100 million in the course of the mortgage time period. The construction provides enhanced operational flexibility, Alvotech claims.
“This €100 million financing underscores the long-term dedication of our financing companions at GoldenTree and their alignment with Alvotech’s technique. Their help strengthens our capacity to execute on our progress plans, spend money on R&D, and ship high-quality biosimilars to sufferers worldwide,” stated Robert Wessman, Chairman and CEO of Alvotech.
Based in 2013 by Wessman, Alvotech goals to be a worldwide chief within the biosimilar area. “A biosimilar is a biologic drugs that’s extremely just like and has no clinically significant variations from an present authorised biologic drugs, or reference product. Biosimilars (like reference merchandise) are produced in dwelling programs,” Alvotech defined on its web site.
In response to the Icelandic firm, 5 biosimilars are already authorised and marketed in a number of international markets, together with biosimilars to Humira® (adalimumab), Stelara® (ustekinumab), Simponi® (golimumab), Eylea® (aflibercept) and Prolia®/Xgeva® (denosumab).
Its present improvement pipeline contains 9 disclosed biosimilar candidates aimed toward treating autoimmune problems, eye problems, osteoporosis, respiratory illness, and most cancers.
In December 2025, Alvotech introduced the profitable placement of €91.9 million ($108 million) senior unsecured convertible bonds due 2030. Moreover, in June 2025, the corporate introduced the repricing of its present facility to an rate of interest of SOFR plus 6.0% each year, equal to roughly 9.8% based mostly on the 30-day common SOFR price of ~3.8%. In June 2024, it introduced the profitable association of a strategic refinancing transaction maturing in June 2029, additionally led by GoldenTree Asset Administration.
Alvotech acknowledged that its R&D pipeline at present contains 30 merchandise in improvement. The corporate is increasing its manufacturing capability and strengthening its provide chain to help 4 international product launches deliberate by 2026.
The corporate claims to have established a community of economic partnerships to help market entry in areas together with america, Europe, Japan, China, different Asian nations, and elements of South America, Africa, and the Center East.
